ClinicalTrials.gg
RecruitingNCT05085067Updated Mar 12, 2025

The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception

An interventional study of auto-crossed-linked hyaluronic acid gel in Retained Products of Conception, sponsored by Fu Xing Hospital, Capital Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Fu Xing Hospital, Capital Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University — 2 open to participants now, 2 under way, none of them phase 3. Gynatresia · Fu Xing Hospital, Capital Medical University.

Started
2022
the only one that year
No phase
7 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University, this one is the only one that started in 2022, is one of 7 with no phase, and was the 9th registered.

Gynatresia

99 studies on the registry are indexed under Gynatresia; 22 are open to participants now.

Browse Gynatresia studies →

Open to participants now

2 of the 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 17 Gynatresia studies recruiting now, 1 (6%) sets no upper age limit and 16 (94%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University, or all of them as a file.
02

Study summary

Retained product of conception (RPOC) is defined by abnormal trophoblastic persistence or retained placenta inside the uterus cavity after a pregnancy independently of the outcome. Untreated RPOC can compromise future fertility. RPOC are generally treated surgically, either by repeated evacuation or by hysteroscopy, which exposes the uterus to additional potential trauma.The combination of trauma to the gravid uterine cavity, hypoestrogenic state at the time of the operation or immediately afterward and local infection is considered to be the pathogenic mechanism of intrauterine adhesions (IUA) , manifested clinically by menstrual abnormalities, infertility and recurrent pregnancy loss.To investigate the efficacy of auto-cross linked hyaluronic acid gel in the prevention of adhesion reformation after hysteroscopic resection of retained products of conception.

After the completion of hysteroscopic resection of retained products of conception, patients will be randomized to one of the two groups by computer-generated numbers: [1] infusing auto-cross linked hyaluronic acid gel into intrauterine cavity in the experimental group; [2] no auto-cross linked hyaluronic acid gel into intrauterine cavity in the control group. Second and third look outpatient hysteroscopy will be performed 4 and 8 weeks after the initial surgery. The patients will be followed up about menstrual pattern at 3 months after the surgery.The patients will be followed up about pregancy outcome at 12 months after the surgery.

03

Conditions studied

  • Retained Products of Conception

Browse trials for

Keywords

  • Retained Products of Conception
  • Hysteroscopy
  • Intrauterine adhesion
  • Auto-crossed-linked hyaluronic acid gel
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of retained products of conception
  • Written consent obtained

Exclusion criteria

Exclusion Criteria:

  • Patients with severe complications of medicine and surgery
  • Acute or chronic genital tract inflammation
  • No understanding or approving the randomized controlled trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • No intervention
    Group A: no auto-cross linked hyaluronic acid gel

    no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception

  • Experimental
    Group B: infusing auto-cross linked hyaluronic acid gel

    infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception

    Other: auto-crossed-linked hyaluronic acid gel

Interventions

  • Otherauto-crossed-linked hyaluronic acid gel

    infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception

06

What researchers measure

Primary outcomes

  1. Adhesion reformation rate at third-look hysteroscopy

    Time frame: A third-look hysteroscopy will be carried out 8 weeks after the initial operation.Findings are graded according to the American Fertility Society classification.

  2. Adhesion score at third-look hysteroscopy

    Time frame: A third-look hysteroscopy will be carried out 8 weeks after the initial operation.Findings are graded according to the American Fertility Society classification.

  3. Concentration of the menstrual pattern

    Time frame: at 3 months after the initial surgery

  4. Pregnancy rate

    Time frame: at 12-month after the initial surgery

Secondary outcomes

  1. Rate of complications

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • FuxingHospital,Captital Medical University
    Beijing, Beijing 100038, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 36 months after the start.

Of 46 interventional studies with no phase under Gynatresia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 64. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 20, 2021
StartActual
Apr 1, 2022
Primary completionEst.
Apr 30, 2025
CompletionEst.
May 30, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05085067
Lead sponsor
Fu Xing Hospital, Capital Medical University
Responsible party
Yang Xue (principal investigator, Fu Xing Hospital, Capital Medical University) — Principal investigator
First posted
Oct 20, 2021
Start date
Apr 1, 2022
Primary completion
Apr 30, 2025 (estimated)
Completion
May 30, 2025 (estimated)
Last update
Mar 12, 2025

Study contacts

Xue Yang, Master
Contact
yuanxy515@163.com
8618810957056
Rong Li Huo, Doctor
Contact
fxyykjc2014@sina.com
8601088062032

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion